BCM
TVTX icon

Bayesian Capital Management’s Travere Therapeutics TVTX Stock Holding History

Bayesian Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28,415
Closed -$398K – 1005
2024
Q3 		$398K Buy
+28,415
New +$296K 0.05% 423
2024
Q2 		– Sell
-22,935
Closed -$177K – 1107
2024
Q1 		$177K Buy
+22,935
New +$193K 0.02% 669
2023
Q3 		– Sell
-29,733
Closed -$457K – 1009
2023
Q2 		$457K Buy
+29,733
New +$541K 0.05% 426

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bayesian Capital Management's TVTX Position: Q4 2024 in Review

Bayesian Capital Management sold out of Travere Therapeutics (TVTX) in Q4 2024, closing a stake of 28,415 shares — an estimated $398K sold.

Bayesian Capital Management first reported a position in TVTX in Q2 2023 and held it in 3 quarters. The position peaked at $457K in Q2 2023. 197 funds tracked by Wall St. Rank hold TVTX as of Q4 2024.

  • Bayesian Capital Management reported no remaining Travere Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 28,415 Travere Therapeutics shares in Q4 2024, an estimated $398K.
  • Bayesian Capital Management first reported a position in Travere Therapeutics in Q2 2023 and held it in 3 quarters.
  • Bayesian Capital Management's Travere Therapeutics position peaked at $457K in Q2 2023.
  • 197 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.